Rezultati pretraživanja
  1. 21. ruj 2019.

    ❓Curious about (anti-CD20) in ? Well...we don't know much 🔎about the results 📈 of the "Nobility" phase 2 trial... so it is a bit early to be really enthusiastic 🎉(but has granted a breakthrough therapy designation). Let's wait ⏳ and see.

  2. 6. lis 2019.

    FAQ during my lectures on therapy: what is the value of the different combinations, with (Ven-Obi) or (Ven-Ibru)? Therefore, I produced a Table with an ITT-based reporting of peripheral blood values (as per 2018 guidelines).

  3. 20. lip 2019.

    Please stop by our poster (280) on the results of the safety run of our phase2 GATA study from for R/R pts in Lugano. See you today and tomorrow at 12:30 in front of the poster 😊

    Prikaži ovu nit
  4. 4. lip 2019.

    Fixed duration - vs Chl-O. 432 pts. median age 72y. median CIRS-G 8. PFS HR 0.35. Benefit in high risk . No OS benefit but fup relatively short. 3m post Rx MRD-ve PB (75.5% vs 35.2%)+BM (56.9% vs. 17.1%) Congrats +colleagues

  5. 7. pro 2019.

    Dr Kirsten Fischer of presented an update of the protocol this morning. Long-lasting remissions in patients achieving negative remissions at EOT with & .

  6. The has granted Breakthrough Therapy designation to , a CD20-directed cytolytic antibody, for the treatment of adults with .

  7. 19. ruj 2019.
  8. 7. lip 2017.
  9. 4. lip 2019.

    - or - in 1L ? Its like a haematologists version of the Messi vs Ronaldo debate... Amazing times in .

  10. Overall Survival Benefit in Patients With Rituximab-Refractory Indolent Non-Hodgkin Who Received Plus Bendamustine Induction and Obinutuzumab Maintenance in the GADOLIN Study

  11. GALLIUM trial Follicular , when analyzing by chemo, the advantage of remains only in Bendamustine arm

  12. 1. pro 2019.

    Le Gouill et al 15 pts 1L ++ in cell lymphoma Potent combination All pts responded by end C2 6/8 MRD neg BM 8/8 MRD neg PB Good safety profile Look forward to seeing combination studied further in 1L pts

  13. 23. lip 2016.

    Results of Phase III GADOLIN trial of for follicular - w/ M Trneny:

  14. 8. stu 2019.

    Obinu&$@&mab superior to rituximab in B cell depletion without apparent increase in immunodeficiency side effects. Would be nice to see a side by side comparison in future trials, rather than placebo control.

    Ovo je potencijalno osjetljiv multimedijski sadržaj. Saznajte više
  15. 4. velj

    de la para + en el tratamiento de la leucemia linfocítica crónica no tratada previamente

  16. 3. velj

    Important data suggesting good therapeutic efficacy of plus in high risk .

  17. 31. sij

    + just approved frontline for in Brazil. Important option for patients not eligible for intensive Tx. Nice to see quicker regulatory approvals in Brazil. Interesting how all will be incorporated into practice.

  18. 8. pro 2019.

    proud to discuss and therapy for elderly patient with indolent , followed by with lenalidomide plus at

  19. Prikaži ovu nit
  20. On the heme consult service now and helping to look into approval as an inpatient... not for CLL but for lupus nephritis! Rheum and heme may disagree on HLH management, but this is a pretty impressive (albeit 💰 💰) convergence of fields!

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.